Shots:

• The study evaluates ASC22 (envafolimab, 1 mg/kg, SC, q4w) + Chidamide (10mg, q2w) for 12wks. in patients infected by human immunodeficiency virus (HIV) with antiviral suppression
• The objective of the study is to evaluate the efficacy of dual regimen on the viral reservoirs of latently infected cells in HIV patients
• ASC22 (SC) is a single domain Ab against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection like HBV and HIV

 Ref: PR Newswire | Image: Business Wire